ProfileGDS5678 / 1417386_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 77% 76% 75% 79% 81% 77% 78% 76% 78% 77% 71% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2906578
GSM967853U87-EV human glioblastoma xenograft - Control 25.3086677
GSM967854U87-EV human glioblastoma xenograft - Control 35.2839877
GSM967855U87-EV human glioblastoma xenograft - Control 45.2574176
GSM967856U87-EV human glioblastoma xenograft - Control 54.9954175
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3170679
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6353381
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2824677
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3248878
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2024976
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3409878
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2953577
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4707871
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2875377